Expanding Biochip Applications Promise Payoff
For Life Science and Drug Discovery Companies

The rapid movement of healthcare toward genomics-based medicine is providing makers of biochips & associated technologies the oppor-tunity to capture lucrative rewards in the near future. New analysis from Frost & Sullivan's drug discovery technologies group, World Biochips Markets, projects this industry will surpass the $ 3.3 billion revenue mark by 2004, with the largest share of dollars garnered by the microarray segment.
Multibillion-dollar growth is inevitable as the application biochips continues to expand, especially in the diagnostic and research setting. Pharmacogenomics applications should also serve as a complex, growing market.